Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Non-alcoholic Wernicke encephalopathy presenting as bilateral hearing loss: a case report.

Prosperini L, Stasolla A, Grieco G, Gerace C, Tortorella C.

J Neurol. 2019 Feb 7. doi: 10.1007/s00415-019-09220-4. [Epub ahead of print] No abstract available.

PMID:
30729314
2.

Clinical correlates of 9-hole peg test in a large population of people with multiple sclerosis.

Solaro C, Cattaneo D, Brichetto G, Castelli L, Tacchino A, Gervasoni E, Prosperini L.

Mult Scler Relat Disord. 2019 Jan 28;30:1-8. doi: 10.1016/j.msard.2019.01.043. [Epub ahead of print]

PMID:
30710887
3.

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N; and the MAGNIMS Study Group.

Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26. Review.

PMID:
30587516
4.

Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.

Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S; Italian PML Group.

J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):261-267. doi: 10.1136/jnnp-2018-319208. Epub 2018 Nov 2.

PMID:
30389778
5.

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.

Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group.

J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26.

PMID:
30259178
6.

e-Health and multiple sclerosis: An update.

Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, Abbadessa G, Schmierer K, Solaro C, Prosperini L, Tedeschi G, Giovannoni G, Bonavita S.

Mult Scler. 2018 Nov;24(13):1657-1664. doi: 10.1177/1352458518799629. Epub 2018 Sep 19.

PMID:
30231004
7.

2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes.

Gaetani L, Prosperini L, Mancini A, Eusebi P, Cerri MC, Pozzilli C, Calabresi P, Sarchielli P, Di Filippo M.

J Neurol. 2018 Nov;265(11):2684-2687. doi: 10.1007/s00415-018-9048-8. Epub 2018 Sep 8.

PMID:
30196327
8.

Predicting the profile of increasing disability in multiple sclerosis.

Tomassini V, Fanelli F, Prosperini L, Cerqua R, Cavalla P, Pozzilli C.

Mult Scler. 2018 Aug 2:1352458518790397. doi: 10.1177/1352458518790397. [Epub ahead of print]

PMID:
30070597
9.

Spotlight on postural control in patients with multiple sclerosis.

Prosperini L, Castelli L.

Degener Neurol Neuromuscul Dis. 2018 Apr 3;8:25-34. doi: 10.2147/DNND.S135755. eCollection 2018. Review.

10.

Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.

Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Centonze D, Cortese A, De Fino C, De Giglio L, Elia G, Fantozzi R, Ferraro E, Francia A, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia GA, Millefiorini E, Monteleone F, Nociti V, Salvetti M, Sgarlata E, Pozzilli C.

CNS Drugs. 2018 Oct;32(10):963-970. doi: 10.1007/s40263-018-0543-3.

PMID:
30022464
11.

Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.

Galgani S, Prosperini L, Haggiag S, Tortorella C, Gasperini C.

J Neurol. 2018 Sep;265(9):2152-2153. doi: 10.1007/s00415-018-8976-7. Epub 2018 Jul 17. No abstract available.

PMID:
30019085
12.

Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.

Landi D, Ragonese P, Prosperini L, Nociti V, Haggiag S, Cortese A, Fantozzi R, Pontecorvo S, Ferraro E, Buscarinu MC, Mataluni G, Monteleone F, Salvetti M, Di Battista G, Francia A, Millefiorini E, Gasperini C, Mirabella M, Salemi G, Boffa L, Pozzilli C, Centonze D, Marfia GA.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1272-1278. doi: 10.1136/jnnp-2018-318468. Epub 2018 Jul 3.

PMID:
29970387
13.

Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.

Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M.

Neurology. 2018 Jul 10;91(2):e153-e161. doi: 10.1212/WNL.0000000000005772. Epub 2018 Jun 6.

PMID:
29875218
14.

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group.

J Neurol. 2018 May;265(5):1174-1183. doi: 10.1007/s00415-018-8831-x. Epub 2018 Mar 16.

PMID:
29549468
15.

Balance worsening associated with nabiximols in multiple sclerosis.

Castelli L, Prosperini L, Pozzilli C.

Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649. [Epub ahead of print]

PMID:
29533137
16.

The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis.

Farcomeni A, Cortese A, Sgarlata E, Alunni Fegatelli D, Marfia GA, Buttari F, Mirabella M, De Fino C, Prosperini L, Pozzilli C, Grasso MG, Iasevoli L, Di Battista G, Millefiorini E.

Neuroepidemiology. 2018;50(3-4):105-110. doi: 10.1159/000487005. Epub 2018 Mar 2.

PMID:
29502114
17.

Role of Cerebellar Dentate Functional Connectivity in Balance Deficits in Patients with Multiple Sclerosis.

Tona F, De Giglio L, Petsas N, Sbardella E, Prosperini L, Upadhyay N, Giannì C, Pozzilli C, Pantano P.

Radiology. 2018 Apr;287(1):267-275. doi: 10.1148/radiol.2017170311. Epub 2017 Dec 22.

PMID:
29272214
18.

Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.

Laroni A, Signori A, Maniscalco GT, Lanzillo R, Russo CV, Binello E, Lo Fermo S, Repice A, Annovazzi P, Bonavita S, Clerico M, Baroncini D, Prosperini L, La Gioia S, Rossi S, Cocco E, Frau J, Torri Clerici V, Signoriello E, Sartori A, Zarbo IR, Rasia S, Cordioli C, Cerqua R, Di Sapio A, Lavorgna L, Pontecorvo S, Barrilà C, Saccà F, Frigeni B, Esposito S, Ippolito D, Gallo F, Sormani MP; iMUST group.

Neurology. 2017 Nov 28;89(22):2222-2229. doi: 10.1212/WNL.0000000000004686. Epub 2017 Nov 1.

PMID:
29093064
19.

Active exergames to improve cognitive functioning in neurological disabilities: a systematic review and meta-analysis.

Mura G, Carta MG, Sancassiani F, Machado S, Prosperini L.

Eur J Phys Rehabil Med. 2018 Jun;54(3):450-462. doi: 10.23736/S1973-9087.17.04680-9. Epub 2017 Oct 25. Review.

20.

To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.

Scarpazza C, Prosperini L, De Rossi N, Moiola L, Sormani MP, Gerevini S, Capra R; Italian PML group.

Ann Neurol. 2017 Nov;82(5):697-705. doi: 10.1002/ana.25070. Epub 2017 Oct 31.

PMID:
29023856
21.

Corrigendum to "Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?" [J. Neurol. Sci. 378 (2017) 233-237].

Scarpazza C, Prosperini L, Mancinelli CR, De Rossi N, Lugaresi A, Capobianco M, Moiola L, Naldi P, Imberti L, Gerevini S, Capra R.

J Neurol Sci. 2017 Sep 15;380:19. doi: 10.1016/j.jns.2017.06.037. Epub 2017 Jul 4. No abstract available.

PMID:
28870565
22.

Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.

Rossi F, Prosperini L, De Rossi N, Capra R, Rivanera D, Li X, Cinque P, Passeri L, Pozzilli C, Viscidi R.

Viral Immunol. 2017 Oct;30(8):622-626. doi: 10.1089/vim.2017.0039. Epub 2017 Aug 24.

PMID:
28836899
23.

Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy.

Prosperini L, Scarpazza C, Imberti L, Cordioli C, De Rossi N, Capra R.

J Neurovirol. 2017 Oct;23(5):742-749. doi: 10.1007/s13365-017-0561-9. Epub 2017 Aug 8.

PMID:
28791614
24.

Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.

Latino P, Castelli L, Prosperini L, Marchetti MR, Pozzilli C, Giovannelli M.

Neurol Sci. 2017 Oct;38(10):1841-1848. doi: 10.1007/s10072-017-3078-3. Epub 2017 Aug 1.

PMID:
28766025
25.

High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline.

Gaetani L, Fanelli F, Riccucci I, Eusebi P, Sarchielli P, Pozzilli C, Calabresi P, Prosperini L, Di Filippo M.

J Neurol Sci. 2017 Aug 15;379:236-240. doi: 10.1016/j.jns.2017.06.008. Epub 2017 Jun 9.

PMID:
28716249
26.

Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?

Scarpazza C, Prosperini L, Mancinelli CR, De Rossi N, Lugaresi A, Capobianco M, Moiola L, Naldi P, Imberti L, Gerevini S, Capra R.

J Neurol Sci. 2017 Jul 15;378:233-237. doi: 10.1016/j.jns.2017.05.018. Epub 2017 May 12. Erratum in: J Neurol Sci. 2017 Sep 15;380:19.

PMID:
28566170
27.

Lesion symptom map of cognitive-postural interference in multiple sclerosis.

Ruggieri S, Fanelli F, Castelli L, Petsas N, De Giglio L, Prosperini L.

Mult Scler. 2018 Apr;24(5):653-662. doi: 10.1177/1352458517701313. Epub 2017 Mar 24.

28.

Single-blind, randomized, pilot study combining shiatsu and amitriptyline in refractory primary headaches.

Villani V, Prosperini L, Palombini F, Orzi F, Sette G.

Neurol Sci. 2017 Jun;38(6):999-1007. doi: 10.1007/s10072-017-2888-7. Epub 2017 Mar 10.

PMID:
28283760
29.

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.

Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group.

Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740. Epub 2017 Feb 22.

30.

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.

Prosperini L, de Rossi N, Scarpazza C, Moiola L, Cosottini M, Gerevini S, Capra R; Italian PML study group.

PLoS One. 2016 Dec 20;11(12):e0168376. doi: 10.1371/journal.pone.0168376. eCollection 2016.

31.

Extratemporal herpes encephalitis during natalizumab treatment: A case report.

Haggiag S, Prosperini L, Galgani S, Pozzilli C, Pinnetti C.

Mult Scler Relat Disord. 2016 Nov;10:134-136. doi: 10.1016/j.msard.2016.10.002. Epub 2016 Oct 5.

PMID:
27919480
32.

Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.

Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, Gasperini C, Millefiorini E, Mirabella M, Pozzilli C.

J Neurol. 2017 Feb;264(2):284-294. doi: 10.1007/s00415-016-8343-5. Epub 2016 Nov 22.

PMID:
27878443
33.

Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis.

De Giglio L, Upadhyay N, De Luca F, Prosperini L, Tona F, Petsas N, Pozzilli C, Pantano P.

J Neurol Sci. 2016 Nov 15;370:211-213. doi: 10.1016/j.jns.2016.09.041. Epub 2016 Sep 22. No abstract available.

PMID:
27772761
34.

Task-dependent deterioration of balance underpinning cognitive-postural interference in MS.

Prosperini L, Castelli L, De Luca F, Fabiano F, Ferrante I, De Giglio L.

Neurology. 2016 Sep 13;87(11):1085-92. doi: 10.1212/WNL.0000000000003090. Epub 2016 Aug 12.

PMID:
27521436
35.

A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.

Galassi S, Prosperini L, Logoteta A, Hirsch MN, Fanelli F, De Giglio L, Pozzilli C.

Mult Scler Relat Disord. 2016 Jul;8:99-106. doi: 10.1016/j.msard.2016.05.012. Epub 2016 May 17.

PMID:
27456883
36.

Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features.

Sbardella E, Upadhyay N, Tona F, Prosperini L, De Giglio L, Petsas N, Pozzilli C, Pantano P.

Mult Scler. 2017 Apr;23(4):546-555. doi: 10.1177/1352458516657438. Epub 2016 Jul 18.

PMID:
27411700
37.

Effects of rehabilitation treatment of the upper limb in multiple sclerosis patients and predictive value of neurophysiological measures.

Nociti V, Prosperini L, Ulivelli M, Losavio FA, Bartalini S, Caggiula M, Cioncoloni D, Caliandro P, Minciotti I, Mirabella M, Padua L.

Eur J Phys Rehabil Med. 2016 Dec;52(6):819-826. Epub 2016 Jul 13.

38.

Level of emotion comprehension in children with mid to long term cochlear implant use: How basic and more complex emotion recognition relates to language and age at implantation.

Mancini P, Giallini I, Prosperini L, D'alessandro HD, Guerzoni L, Murri A, Cuda D, Ruoppolo G, De Vincentiis M, Nicastri M.

Int J Pediatr Otorhinolaryngol. 2016 Aug;87:219-32. doi: 10.1016/j.ijporl.2016.06.033. Epub 2016 Jun 15.

PMID:
27368475
39.

Assessing response to interferon-β in a multicenter dataset of patients with MS.

Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group.

Neurology. 2016 Jul 12;87(2):134-40. doi: 10.1212/WNL.0000000000002830. Epub 2016 Jun 15.

PMID:
27306626
40.

Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.

Annovazzi P, Capobianco M, Moiola L, Patti F, Frau J, Uccelli A, Centonze D, Perini P, Tortorella C, Prosperini L, Lus G, Fuiani A, Falcini M, Martinelli V, Comi G, Ghezzi A.

J Neurol. 2016 Sep;263(9):1727-35. doi: 10.1007/s00415-016-8188-y. Epub 2016 Jun 10.

PMID:
27286847
41.

A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.

Truini A, Prosperini L, Calistri V, Fiorelli M, Pozzilli C, Millefiorini E, Frontoni M, Cortese A, Caramia F, Cruccu G.

Neurology. 2016 May 31;86(22):2094-9. doi: 10.1212/WNL.0000000000002720. Epub 2016 May 4.

PMID:
27164695
42.

Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis.

Prosperini L, Fanelli F, Pozzilli C.

J Neurol Sci. 2016 May 15;364:145-7. doi: 10.1016/j.jns.2016.03.025. Epub 2016 Mar 16.

PMID:
27084235
43.

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations.

Prosperini L, Pontecorvo S.

Ther Clin Risk Manag. 2016 Mar 2;12:339-50. doi: 10.2147/TCRM.S85099. eCollection 2016. Review.

44.

Multiple Sclerosis: Changes in Thalamic Resting-State Functional Connectivity Induced by a Home-based Cognitive Rehabilitation Program.

De Giglio L, Tona F, De Luca F, Petsas N, Prosperini L, Bianchi V, Pozzilli C, Pantano P.

Radiology. 2016 Jul;280(1):202-11. doi: 10.1148/radiol.2016150710. Epub 2016 Mar 8.

PMID:
26953867
45.

The dual task-cost of standing balance affects quality of life in mildly disabled MS people.

Castelli L, De Luca F, Marchetti MR, Sellitto G, Fanelli F, Prosperini L.

Neurol Sci. 2016 May;37(5):673-9. doi: 10.1007/s10072-015-2456-y. Epub 2016 Jan 4.

PMID:
26728268
46.

Cost-Effectiveness of Escalating to Natalizumab or Switching Among Immunomodulators In Relapsing-Remitting Multiple Sclerosis In Italy.

Furneri G, Santoni L, Ricella C, Prosperini L.

Value Health. 2015 Nov;18(7):A695. doi: 10.1016/j.jval.2015.09.2588. Epub 2015 Oct 20. No abstract available.

47.

We-Measure: Toward a low-cost portable posturography for patients with multiple sclerosis using the commercial Wii balance board.

Castelli L, Stocchi L, Patrignani M, Sellitto G, Giuliani M, Prosperini L.

J Neurol Sci. 2015 Dec 15;359(1-2):440-4. doi: 10.1016/j.jns.2015.10.016. Epub 2015 Oct 14.

PMID:
26490321
48.

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.

Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M; Italian iMed-Web database.

Brain. 2015 Nov;138(Pt 11):3275-86. doi: 10.1093/brain/awv260. Epub 2015 Sep 11.

PMID:
26362907
49.

The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma.

Villani V, Casini B, Pace A, Prosperini L, Carapella CM, Vidiri A, Fabi A, Carosi M.

Dis Markers. 2015;2015:604719. doi: 10.1155/2015/604719. Epub 2015 Aug 11.

50.

Relationship between Prolactin Plasma Levels and White Matter Volume in Women with Multiple Sclerosis.

De Giglio L, Marinelli F, Prosperini L, Contessa GM, Gurreri F, Piattella MC, De Angelis F, Barletta VT, Tomassini V, Pantano P, Pozzilli C.

Mediators Inflamm. 2015;2015:732539. doi: 10.1155/2015/732539. Epub 2015 Jul 8.

Supplemental Content

Loading ...
Support Center